Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 242

1.

CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.

Olivier RI, Lubsen-Brandsma MA, Verhoef S, van Beurden M.

Gynecol Oncol. 2006 Jan;100(1):20-6. Epub 2005 Sep 26.

PMID:
16188302
2.

Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?

van der Velde NM, Mourits MJ, Arts HJ, de Vries J, Leegte BK, Dijkhuis G, Oosterwijk JC, de Bock GH.

Int J Cancer. 2009 Feb 15;124(4):919-23. doi: 10.1002/ijc.24038.

3.

Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective.

Woodward ER, Sleightholme HV, Considine AM, Williamson S, McHugo JM, Cruger DG.

BJOG. 2007 Dec;114(12):1500-9. Epub 2007 Sep 27.

4.

Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.

Meeuwissen PA, Seynaeve C, Brekelmans CT, Meijers-Heijboer HJ, Klijn JG, Burger CW.

Gynecol Oncol. 2005 May;97(2):476-82.

PMID:
15863147
5.

Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study.

Gaarenstroom KN, van der Hiel B, Tollenaar RA, Vink GR, Jansen FW, van Asperen CJ, Kenter GG.

Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:54-9.

PMID:
16515568
6.

Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study.

Bosse K, Rhiem K, Wappenschmidt B, Hellmich M, Madeja M, Ortmann M, Mallmann P, Schmutzler R.

Gynecol Oncol. 2006 Dec;103(3):1077-82. Epub 2006 Aug 9.

PMID:
16904167
7.

Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing.

Schwartz MD, Kaufman E, Peshkin BN, Isaacs C, Hughes C, DeMarco T, Finch C, Lerman C.

J Clin Oncol. 2003 Nov 1;21(21):4034-41.

PMID:
14581427
8.

[Screening pelvic tumours for hereditary risk of ovarian neoplasms, a cancer center experience].

Taïeb S, Rocourt N, Narducci F, Leblanc E, Adenis C, Fournier C, Doutrelant P, Peyrat JP, Vennin P.

Bull Cancer. 2011 Feb;98(2):113-9. doi: 10.1684/bdc.2011.1302. French.

9.

Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.

Chen Y, Bancroft E, Ashley S, Arden-Jones A, Thomas S, Shanley S, Saya S; Carrier Clinic Collaborators, Wakeling E, Eeles R.

Fam Cancer. 2014 Jun;13(2):197-203. doi: 10.1007/s10689-013-9697-9.

PMID:
24389956
10.

A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value.

Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC Jr.

Cancer. 2013 Oct 1;119(19):3454-61. doi: 10.1002/cncr.28183. Epub 2013 Aug 26.

11.
12.

Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study.

Cortesi L, De Matteis E, Toss A, Marchi I, Medici V, Contu G, Xholli A, Grandi G, Cagnacci A, Federico M.

Oncology. 2017;93(6):377-386. doi: 10.1159/000479155. Epub 2017 Aug 26.

PMID:
28848147
13.

Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers.

Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dørum A, Steel M, Lalloo F, Apold J, Porteous ME, Vasen HF, van Asperen CJ, Moller P.

J Med Genet. 2009 Sep;46(9):593-7. doi: 10.1136/jmg.2008.058248. Epub 2008 Apr 15.

PMID:
18413372
14.

Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.

Olivier RI, van Beurden M, Lubsen MA, Rookus MA, Mooij TM, van de Vijver MJ, van't Veer LJ.

Br J Cancer. 2004 Apr 19;90(8):1492-7.

15.

Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.

Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SJ, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH.

J Clin Oncol. 2014 Oct 10;32(29):3275-83. doi: 10.1200/JCO.2013.54.1987. Epub 2014 Sep 8.

16.

Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system.

Stirling D, Evans DG, Pichert G, Shenton A, Kirk EN, Rimmer S, Steel CM, Lawson S, Busby-Earle RM, Walker J, Lalloo FI, Eccles DM, Lucassen AM, Porteous ME.

J Clin Oncol. 2005 Aug 20;23(24):5588-96.

PMID:
16110018
17.

Surveillance of women at high risk for hereditary ovarian cancer is inefficient.

Oei AL, Massuger LF, Bulten J, Ligtenberg MJ, Hoogerbrugge N, de Hullu JA.

Br J Cancer. 2006 Mar 27;94(6):814-9.

19.

The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.

Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, Tamura R, Timor-Tritsch I, Schwartz PE.

Am J Obstet Gynecol. 2005 Apr;192(4):1214-21; discussion 1221-2.

PMID:
15846205
20.

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I.

Lancet Oncol. 2009 Apr;10(4):327-40. doi: 10.1016/S1470-2045(09)70026-9. Epub 2009 Mar 11.

Supplemental Content

Support Center